2 results
Approved WMOWill not start
To determine whether aleglitazar reduces cardiovasculair mortality and morbidity (defined as non-fatal myocardial infarction (MI) and non-fatal stroke) in patients with a recent ACS event and type 2 diabetes.
Approved WMOCompleted
To test the feasibility of supplying a tailored, digital health app, designed to increase insight in how to reduce one*s dementia risk, in the general practice. Secondly, we aim to explore the usability of experience-sampling method (ESM) technology…